TheraRadar
← Back
Data updated: Jun 28, 2026

UNIQUE

Generics

UNIQUE is a generic drug manufacturer focused on Cardiovascular, Neurology, Immunology.

2004
Since
22
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

UNIQUE's Key Drugs

UNIQUE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

UNIQUE's Recent FDA Approvals

New NDA/BLA approvals for UNIQUE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

UNIQUE's Therapeutic Areas

UNIQUE's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
4 drugs
Neurology 13%
1 drugs
Immunology 13%
1 drugs
Infectious Disease 13%
1 drugs
Dermatology 13%
1 drugs

UNIQUE Pipeline Snapshot

Active clinical trials for UNIQUE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling